Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
From BeiGene
Via Business Wire
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
BeiGene Introduces Global Environmental, Social, and Governance Strategy
From BeiGene, Ltd.
Via Business Wire
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
From BeiGene
Via Business Wire
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
From BeiGene
Via Business Wire
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
From BeiGene
Via Business Wire
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
From BeiGene
Via Business Wire
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
From BeiGene, Ltd.
Via Business Wire
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
From BeiGene
Via Business Wire
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From BeiGene
Via Business Wire
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
From BeiGene
Via Business Wire
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
From BeiGene
Via Business Wire
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
From BeiGene
Via Business Wire
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
From BeiGene
Via Business Wire
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
From BeiGene, Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.